In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Prof. Jose Karam on the results of the LITESPARK-022 study: Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomised phase 3 LITESPARK-022 study. The LITESPARK-022 study will be also presented and discussed at the upcoming EAU26 on Saturday 14th March in the Game Changer Session. Don't miss the chance to hear more on this important study. This interview was recorded...